ORPHA:1046
Lethal hemolytic anemia-genital anomalies syndrome
Also known as: Water-West syndrome
Publications
0
Trials
0
Interventional, condition-specific
Researchers
0
Distinct authors in sample
Gene link
—
Readiness
0/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic disease characterized by lethal non-spherocytic, non-immune hemolytic anemia, in association with abnormalities of the external genitalia (such as micropenis and hypospadias). Reported features include flat occiput, dimpled earlobes, deep plantar creases, and increased space between the first and second toes. There have been no further descriptions in the literature since 1995.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010891
- MeSH:C563935
- OMIM:600461
- UMLS:C1838120
Additional Mondo synonyms (1)
water-West syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
0/6 stages with a signal
Search queries returned nothing — this usually means a naming mismatch, not proof that nothing exists.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteratureNot checked
Query returned nothing — not evidence of absence Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot checked
Broken query — trial zero not trusted
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
0
We found no papers under this exact name — work may still exist under another label.
0 in the last 10 years · low confidence
Phrase hits: 0 · MeSH hits: 0
Who's working on it?
0
Distinct author names in 0 sampled papers.
Who's working on it?
No author names could be extracted from the sampled publications. Try the Europe PMC query in “How we counted this,” or contact an umbrella rare-disease organisation for researcher referrals.
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 83 trials are registered for hemolytic anemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
83 interventional trials matched hemolytic anemia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: hemolytic anemia
83
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07091370·NOT YET RECRUITING·Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
Conditions: AIHA - Cold Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT07441525·RECRUITING·UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
Conditions: Autoimmune Hemolytic Anemia · Primary Immune Thrombocytopenic Purpura · Evans Syndrome·Matched via name phrase
- NCT07083960·RECRUITING·OM336 in Autoimmune Cytopenias
Conditions: AIHA - Warm Autoimmune Hemolytic Anemia · AIHA - Cold Autoimmune Hemolytic Anemia · ITP - Immune Thrombocytopenia·Matched via name phrase
- NCT07039422·RECRUITING·Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Conditions: Primary Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT07603557·NOT YET RECRUITING·Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Conditions: Chronic Immune Thrombocytopenia · Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT07629596·RECRUITING·Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
Conditions: Systemic Lupus Erythematosus · Autoimmune Hemolytic Anemia (AIHA)·Matched via name phrase
- NCT05089227·RECRUITING·Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study
Conditions: Prolonged Anticoagulation · Venous Thromboembolic Disease · Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT04138927·ENROLLING BY INVITATION·A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Conditions: Warm Antibody Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT07175493·RECRUITING·A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Conditions: Autoimmune Cytopenia · Immune Thrombocytopenia (ITP) · Autoimmune Hemolytic Anemia · Evans Syndrome·Matched via name phrase
- NCT07190261·NOT YET RECRUITING·A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
Conditions: Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT05925023·RECRUITING·Sirolimus in the Treatment of Refractory/Relapsed wAIHA
Conditions: Warm Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT06888960·RECRUITING·Safety Study of CC312 in Autoimmune Disease Patients
Conditions: Systemic Lupus Erythematosus (SLE) · Idiopathic Inflammatory Myopathy (IIM) · Systemic Sclerosis (SSc) · Rheumatoid Arthritis (RA)·Matched via name phrase
- NCT07530380·RECRUITING·UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
Conditions: AIHA - Warm Autoimmune Hemolytic Anemia · UCART·Matched via name phrase
- NCT07518277·NOT YET RECRUITING·A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia
Conditions: Autoimmune Hemolytic Anemia (AIHA)·Matched via name phrase
- NCT07361094·RECRUITING·Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Conditions: Relapsed/Refractory Systemic Lupus Erythematosus · Relapsed/Refractory Systemic Sclerosis · Relapsed/Refractory Idiopathic Inflammatory Myopathies · Relapsed/Refractory sjögren's Syndrome·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Lethal hemolytic anemia-genital anomalies syndrome" OR "Water-West syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Lethal hemolytic anemia-genital anomalies syndrome" OR "Water-West syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemolytic anemia"
Query health: broken — strategies attempted: phrase; with hits: none
Parent literature probe: syndromic disease (MONDO:0002254) — 1116 hits
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Zero publications but parent term syndromic disease has 1116 — literature likely indexed under a broader name
Ingested 2026-07-26T16:15:59.245Z · excluded from neglect metrics
